Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approval of Intragastric Balloon System

Device assists adults with weight management

Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.

Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.

Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.

Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.

This Week's Must Reads

Efficacy of Glecaprevir-Pibrentasvir in HCV, N Engl J Med; 2018 Jan 25; Zeuzem, et al

Cigarette Smoking in Persons Living with HCV, Am J Med; ePub 2018 Feb 3; Kim, et al

Expanded Age-Based HCV Testing in US , Clin Infect Dis; ePub 2018 Feb 6; Barocas, et al

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

HCV Incidence From Injection Paraphernalia , J Infect Dis; 2018 Jan; Heimer, Binka, et al

Must Reads in Obesity

Bariatric Surgery and All-Cause Mortality, JAMA; 2018 Jan 16; Reges, Greenland, et al

Fiber Supplementation and Metabolic Outcomes, Am J Clin Nutr; 2017 Dec; Thompson, et al

Risk of Obesity From Childhood into Adulthood, N Engl J Med; 2017 Nov 30; Ward, Long, et al

Weight Loss Diets & All-Cause Mortality, BMJ; ePub 2017 Nov 14; Ma, Avenell, et al

Cancer Risk in Overweight & Obese Individuals, MMWR; ePub 2017 Oct 3; Steele, et al